

NZX/ASX Announcement

9 March 2023

Pitt Street Research Report

An issuer sponsored Research Report prepared by leading biotech analyst Stuart Roberts of Pitt Street Research Pty Ltd was published by Pitt Street Research on 7 March 2023.

A copy of the report is available on the Company's website at: https://truscreen.com/pitt-street-2023/

ENDS

For more information, visit <u>www.truscreen.com</u> or contact:

Dr Beata Edling Chief Executive Officer beataedling@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com Julia Maguire Investor Relations julia@thecapitalnetwork.com.au

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical cancer screening programmes and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

To learn more, please visit: www.truscreen.com/